Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Addex Therapeutics (ADXN) Competitors

Addex Therapeutics logo
$7.00 +0.17 (+2.49%)
Closing price 05/19/2026 03:59 PM Eastern
Extended Trading
$6.67 -0.33 (-4.70%)
As of 05/19/2026 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ADXN vs. RNTX, VIRI, BTAI, APLM, and TVGN

Should you buy Addex Therapeutics stock or one of its competitors? MarketBeat compares Addex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Addex Therapeutics include Rein Therapeutics (RNTX), Virios Therapeutics (VIRI), BioXcel Therapeutics (BTAI), Apollomics (APLM), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.

How does Addex Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rein Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

In the previous week, Rein Therapeutics had 6 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for Rein Therapeutics and 0 mentions for Addex Therapeutics. Rein Therapeutics' average media sentiment score of 1.15 beat Addex Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Rein Therapeutics Positive
Addex Therapeutics Neutral

Addex Therapeutics has higher revenue and earnings than Rein Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.90N/A
Addex Therapeutics$210K41.00$8.02M-$5.74N/A

Addex Therapeutics' return on equity of -80.69% beat Rein Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A -510.35% -68.14%
Addex Therapeutics N/A -80.69%-69.69%

Rein Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 704.02%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Rein Therapeutics beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Virios Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Addex Therapeutics' return on equity of -80.69% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -80.69% -69.69%
Virios Therapeutics N/A -130.33%-115.00%

Addex Therapeutics has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Addex Therapeutics has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K41.00$8.02M-$5.74N/A
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company Overall Sentiment
Addex Therapeutics Neutral
Virios Therapeutics Neutral

Summary

Addex Therapeutics beats Virios Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Addex Therapeutics compare to BioXcel Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Addex Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K41.00$8.02M-$5.74N/A
BioXcel Therapeutics$640K52.11-$69.90M-$5.75N/A

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 918.52%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioXcel Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Addex Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -80.69% -69.69%
BioXcel Therapeutics -11,078.53%N/A -201.53%

In the previous week, BioXcel Therapeutics had 3 more articles in the media than Addex Therapeutics. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 0 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 beat BioXcel Therapeutics' score of -1.09 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Addex Therapeutics Neutral
BioXcel Therapeutics Negative

Addex Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BioXcel Therapeutics beats Addex Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Addex Therapeutics compare to Apollomics?

Addex Therapeutics (NASDAQ:ADXN) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Apollomics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Addex Therapeutics has higher earnings, but lower revenue than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K41.00$8.02M-$5.74N/A
Apollomics$8.50M3.72-$10.94MN/AN/A

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Addex Therapeutics Neutral
Apollomics Neutral

Apollomics' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -80.69% -69.69%
Apollomics N/A N/A N/A

Addex Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Summary

Apollomics beats Addex Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Addex Therapeutics compare to Tevogen Bio?

Addex Therapeutics (NASDAQ:ADXN) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Tevogen Bio had 3 more articles in the media than Addex Therapeutics. MarketBeat recorded 3 mentions for Tevogen Bio and 0 mentions for Addex Therapeutics. Tevogen Bio's average media sentiment score of 1.08 beat Addex Therapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Addex Therapeutics Neutral
Tevogen Bio Positive

Addex Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 913.17%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Addex Therapeutics has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K41.00$8.02M-$5.74N/A
Tevogen BioN/AN/A-$26.27M-$6.50N/A

Tevogen Bio's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -80.69% -69.69%
Tevogen Bio N/A N/A -472.77%

Summary

Addex Therapeutics beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXN vs. The Competition

Export
MetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.41M$2.99B$6.25B$12.23B
Dividend YieldN/A1.96%2.80%5.32%
P/E Ratio-1.2217.0420.7925.05
Price / Sales41.00251.21531.2172.69
Price / CashN/A57.1543.0954.25
Price / Book0.684.399.816.83
Net Income$8.02M$74.99M$3.55B$335.69M
7 Day Performance-1.20%-5.15%-2.12%-2.15%
1 Month Performance8.11%-8.25%-4.14%-2.47%
1 Year Performance-13.21%26.23%28.34%27.13%

Addex Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADXN
Addex Therapeutics
0.8089 of 5 stars		$7.00
+2.5%		N/A-13.5%$8.41M$210KN/A30
RNTX
Rein Therapeutics
3.414 of 5 stars		$1.17
+4.5%		$8.00
+583.8%		-53.7%$32.81MN/AN/A9
VIRI
Virios Therapeutics
N/A$1.70
+0.6%		N/A-68.0%$32.74MN/AN/A5
BTAI
BioXcel Therapeutics
1.8021 of 5 stars		$1.19
-0.4%		$11.00
+828.3%		-25.0%$32.09M$640KN/A90
APLM
Apollomics
0.7654 of 5 stars		$13.88
-5.3%		N/A+165.8%$30.53M$8.50MN/A45

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 5/20/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book attached
Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...
Profits Run | Sponsoredtc pixel
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...
Behind the Markets | Sponsoredtc pixel
He doesn't buy gold. He just profits from it.
Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...
Brownstone Research | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel